🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

97+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 97 recruiting trials for “acute-erythroid-leukemia

Phase 1RecruitingNCT06357182

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

👨‍⚕️ Curtis A Lachowiez, OHSU Knight Cancer Institute📍 1 site📅 Started Aug 2024View details ↗
Phase 1RecruitingNCT06399640

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

👨‍⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT06529250

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

👨‍⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06377579

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

👨‍⚕️ Pierre PETERLIN, Dr, French Innovative Leukemia Organisation📍 21 sites📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06536959

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

🏥 Beijing 302 Hospital📍 1 site📅 Started Jul 2024View details ↗
Phase 4RecruitingNCT06571825

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

🏥 He Huang📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06483906

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

👨‍⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
EARLY_Phase 1RecruitingNCT06541405

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

👨‍⚕️ wenting Hu, Shanghai children's medical center📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT06382168

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

🏥 Delta-Fly Pharma, Inc.📍 4 sites📅 Started Jun 2024View details ↗
Phase 1RecruitingNCT06419634

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 15 sites📅 Started May 2024View details ↗
Phase 1RecruitingNCT06465160

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

🏥 Minovia Therapeutics Ltd.📍 1 site📅 Started May 2024View details ↗
Phase 1RecruitingNCT06378437

A Study of GLB-001 in Patients With Myeloid Malignancies

👨‍⚕️ Gang Lu, Ph.D., Hangzhou GluBio Pharmaceutical Co., Ltd.📍 14 sites📅 Started May 2024View details ↗
Phase 2RecruitingNCT05483010

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

👨‍⚕️ Amber Afzal, M.D., MSCI, Washington University School of Medicine📍 1 site📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06232655

Cladribine Venetoclax in Monocytic AML

👨‍⚕️ Christine McMahon, MD, University of Colorado, Denver📍 1 site📅 Started Feb 2024View details ↗
Phase 1RecruitingNCT05947344

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

🏥 Zhejiang ACEA Pharmaceutical Co. Ltd.📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06116318

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Nov 2023View details ↗
Phase 1RecruitingNCT05995041

Universal CAR-T Cells Targeting AML

🏥 Shenzhen Geno-Immune Medical Institute📍 1 site📅 Started Oct 2023View details ↗
NARecruitingNCT06066242

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

👨‍⚕️ Hui Wei, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Oct 2023View details ↗
Phase 1RecruitingNCT05735184

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

🏥 Kura Oncology, Inc.📍 44 sites📅 Started Jul 2023View details ↗
Phase 3RecruitingNCT05994690

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

👨‍⚕️ Gertjan Kaspers, Prof. Dr., Pediatric Oncologist📍 1 site📅 Started Jul 2023View details ↗
← PreviousPage 3 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →